Search Results
You are looking at 11 - 18 of 18 items for
- Author: S Li x
- Refine by access: All content x
Search for other papers by V K Turan in
Google Scholar
PubMed
Search for other papers by R I Sanchez in
Google Scholar
PubMed
Search for other papers by J J Li in
Google Scholar
PubMed
Search for other papers by S A Li in
Google Scholar
PubMed
Search for other papers by K R Reuhl in
Google Scholar
PubMed
Search for other papers by P E Thomas in
Google Scholar
PubMed
Search for other papers by A H Conney in
Google Scholar
PubMed
Search for other papers by M A Gallo in
Google Scholar
PubMed
Search for other papers by F C Kauffman in
Google Scholar
PubMed
Search for other papers by S Mesia-Vela in
Google Scholar
PubMed
Several investigators have suggested that certain hydroxylated metabolites of 17β-estradiol (E2) are the proximate carcinogens that induce mammary carcinomas in estrogen-sensitive rodent models. The studies reported here were designed to examine the carcinogenic potential of different levels of E2 and the effects of genotoxic metabolites of E2 in an in vivo model sensitive to E2-induced mammary cancer. The potential induction of mammary tumors was determined in female ACI rats subcutaneously implanted with cholesterol pellets containing E2 (1, 2, or 3 mg), or 2-hydroxyestradiol (2-OH E2), 4-hydroxyestradiol (4-OH E2), 16α-hydroxyestradiol (16α-OH E2), or 4-hydoxyestrone (4-OH E1) (equimolar to 2 mg E2). Treatment with 1, 2, or 3 mg E2 resulted in the first appearance of a mammary tumor between 12 and 17 weeks, and a 50% incidence of mammary tumors was observed at 36, 19, and 18 weeks respectively. The final cumulative mammary tumor incidence in rats treated with 1, 2, or 3 mg E2 for 36 weeks was 50%, 73%, and 100% respectively. Treatment of rats with pellets containing 2-OH E2, 4-OH E2, 16α-OH E2, or 4-OH E1 did not induce any detectable mammary tumors. The serum levels of E2 in rats treated with a 1 or 3 mg E2 pellet for 12 weeks was increased 2- to 6-fold above control values (~30 pg/ml). Treatment of rats with E2 enhanced the hepatic microsomal metabolism of E2 to E1, but did not influence the 2- or 4-hydroxylation of E2. In summary, we observed a dose-dependent induction of mammary tumors in female ACI rats treated continuously with E2; however, under these conditions 2-OH E2, 4-OH E2, 16α-OH E2, and 4-OH E1 were inactive in inducing mammary tumors.
Search for other papers by W M Lee in
Google Scholar
PubMed
Search for other papers by A S T Wong in
Google Scholar
PubMed
Search for other papers by A W K Tu in
Google Scholar
PubMed
Search for other papers by C-H Cheung in
Google Scholar
PubMed
Search for other papers by J C H Li in
Google Scholar
PubMed
Search for other papers by G L Hammond in
Google Scholar
PubMed
Abstract
Sex hormone binding globulin (SHBG) is a homodimeric plasma protein found in mammals that binds sex steroids with high affinity and regulates their bioavailability. The protein is identical in structure and properties to the androgen binding protein (ABP) found in the male reproductive tract. We have isolated a 1245-base pair rabbit SHBG cDNA encoding a reading frame for a signal peptide followed by a protein of 367 amino acids, which shares 79·0, 68·1 and 63·2% amino acid identity with the corresponding human, rat and mouse proteins respectively. Northern blot and hot-nested PCR analyses indicated that rabbit SHBG is produced from a 1·6 kilobase mRNA in the liver of both sexes and in the testis. The rabbit SHBG cDNA was inserted into pGEX-1λT for expression of a glutathione S-transferase/SHBG fusion protein in Escherichia coli. The bacterial product bound 5α-dihydrotestosterone (DHT) in the same manner as the corresponding protein in serum. The dissociation constants (Kd) for rabbit and human SHBGs produced in E. coli were 11·1 ± 1·1 nm and 2·1 ± 0·6 nm respectively, and rabbit SHBG formed a less stable protein-steroid complex (t½=5 min) than human SHBG (t½>60 min). Unlike human SHBG, rabbit SHBG does not bind estradiol with high affinity. To aid in the identification of differences in the sequences of rabbit and human SHBG, which determine species differences in steroid-binding affinity and specificity, chimeras containing the 5′-terminal half of SHBG from one species and 3′-terminal half of SHBG from the other species were constructed and expressed. It was found that the chimeric proteins assumed similar steroid-binding affinity and specificity as the wild-type proteins when the amino (N)-terminal half of SHBG was derived from the same species. Replacement of the carboxyl (C)-terminal half of rabbit SHBG by the corresponding region of the human molecule increased the integrity of its steroid-protein complex. This supports the concept that amino acids within the N-terminal half of SHBG constitute the steroid-binding domain while the C-terminal half of the molecule may provide structural stability to the protein and its steroid-binding site.
Journal of Endocrinology (1997) 153, 373–384
Search for other papers by R J M Ross in
Google Scholar
PubMed
Search for other papers by S L Chew in
Google Scholar
PubMed
Search for other papers by L D'Souza Li in
Google Scholar
PubMed
Search for other papers by M Yateman in
Google Scholar
PubMed
Search for other papers by J Rodriguez-Arnao in
Google Scholar
PubMed
Search for other papers by A Gimson in
Google Scholar
PubMed
Search for other papers by J Holly in
Google Scholar
PubMed
Search for other papers by C Camacho-Hubner in
Google Scholar
PubMed
Abstract
The liver plays a central role in the IGF-I axis producing the majority of circulating hormone and some of its binding proteins (IGFBPs). Cirrhosis of the liver is characterised by changes in IGF-I and IGFBPs associated with liver fibrosis and regeneration. We have studied steady state levels of mRNA for the genes in the IGF-I axis in normal and cirrhotic human liver, localised the most highly expressed gene, IGFBP-1, and measured circulating IGFBP-3 by radioimmunoassay (RIA), IGFBP-2 and IGFBP-3 by Western ligand blot (WLB), and protease activity for IGFBP-3 in cirrhotic patients. Messenger RNA for IGF-I, IGFBP-1, IGFBP-2, and IGFBP-3 was detectable by Northern blotting in normal and cirrhotic liver although there was considerable variation in expression. IGFBP-2 and IGFBP-3 tended to be more highly expressed in cirrhotic liver and IGFBP-1 was more highly expressed in normal liver, although there were no significant differences. In normal liver, in situ hybridisation localised IGFBP-1 to hepatocytes. In cirrhotic liver the regenerating nodules showed expression of IGFBP-1 while there was none in fibrotic tissue. Circulating IGFBP-3 levels were low as measured by RIA and WLB but protease activity was only found in one patient. IGFBP-2 levels, assessed by WLB, were similar to the normal serum pool. Our data show that key mRNAs involved in the IGF-I axis continue to be expressed in cirrhotic liver despite end stage liver disease. The low levels of IGFBP-3 do not appear to be due to reduced gene transcription or increased protease activity.
Journal of Endocrinology (1996) 149, 209–216
Search for other papers by H Y Li in
Google Scholar
PubMed
Danone Nutricia Research, Singapore, Republic of Singapore
Search for other papers by Y X Liu in
Google Scholar
PubMed
Search for other papers by L Harvey in
Google Scholar
PubMed
Search for other papers by S Shafaeizadeh in
Google Scholar
PubMed
Department of Pediatrics, University Medical Centre Groningen, Groningen, The Netherlands
Search for other papers by E M van der Beek in
Google Scholar
PubMed
Institute of Molecular and Cell Biology, A*STAR, Singapore, Republic of Singapore
School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, Zhejiang, China
Search for other papers by W Han in
Google Scholar
PubMed
The prevalence of gestational diabetes mellitus (GDM) is estimated at 14% globally, and in some countries, such as Singapore, exceeds 20%. Both women and children exposed to GDM have an increased risk of later metabolic diseases, cardiovascular disease and other health issues. Beyond lifestyle changes and pharmaceutical intervention using existing type 2 diabetes medications for expecting women, there are limited treatment options for women with GDM; targeting better outcomes of potentially affected infants is unexplored. Numerous animal models have been generated for understanding of pathological processes of GDM development and for development of treatment strategies. These models, however, suffer from limited windows of opportunity to examine risk factors and potential intervention options. By combining short-term high-fat diet (HFD) feeding and low-dose streptozotocin (STZ) treatments before pregnancy, we have established a mouse model with marked transient gestation-specific hyperglycemia, which allows testing of nutritional and pharmacological interventions before, during and beyond pregnancy.
Search for other papers by BS Moonga in
Google Scholar
PubMed
Search for other papers by OA Adebanjo in
Google Scholar
PubMed
Search for other papers by HJ Wang in
Google Scholar
PubMed
Search for other papers by S Li in
Google Scholar
PubMed
Search for other papers by XB Wu in
Google Scholar
PubMed
Search for other papers by B Troen in
Google Scholar
PubMed
Search for other papers by A Inzerillo in
Google Scholar
PubMed
Search for other papers by E Abe in
Google Scholar
PubMed
Search for other papers by C Minkin in
Google Scholar
PubMed
Search for other papers by CL Huang in
Google Scholar
PubMed
Search for other papers by M Zaidi in
Google Scholar
PubMed
The effects of the related cytokines interleukin-6 (IL-6), leukemia inhibitory factor (LIF) and oncostatin-M on bone resorption and cytosolic Ca(2+) signaling were compared in isolated rat osteoclasts. In the traditional disaggregated osteoclast (pit) assay, IL-6 and LIF, but not oncostatin-M, conserved the bone resorption otherwise inhibited by high extracellular [Ca(2+)] (15 mM). It produced a paradoxical, concentration-dependent stimulation of resorption by elevated extracellular Ca(2+). In the micro-isolated single osteoclast resorption assay, IL-6, high [Ca(2+)] or IL-6 plus high [Ca(2+)] all increased pit formation. In contrast, the IL-6 receptor (IL-6R)-specific agonist antibody MT-18 inhibited bone resorption in a concentration-dependent manner (1:500 to 1:500 000). MT-18 triggered cytosolic Ca(2+) signals in fura 2-loaded osteoclasts within approximately 10 min of application. Each cytosolic Ca(2+) transient began with a peak deflection that persisted in Ca(2+)-free, EGTA-containing extracellular medium, consistent with a release of intracellularly stored Ca(2+). This was followed by a sustained elevation of cytosolic [Ca(2+)] that was abolished in Ca(2+)-free medium, as expected from an entry of extracellular Ca(2+), and by the Ca(2+) channel antagonist Ni(2+). The inclusion of either IL-6 or soluble human (sh) IL-6R specifically reversed both the above effects of MT-18, confirming that both effects were specific for the IL-6R. The findings suggest that IL-6R activation by IL-6 stimulates osteoclastic bone resorption either by reversing the inhibitory effect of high extracellular Ca(2+) in stromal-containing systems or itself stimulating bone resorption along with Ca(2+) by micro-isolated osteoclasts. In contrast, activation of the IL-6R by an agonist antibody produces an inhibition of bone resorption and an associated triggering of the cytosolic Ca(2+) signals previously associated with regulation of bone resorptive function in other situations.
Search for other papers by Y Yang in
Google Scholar
PubMed
Search for other papers by J Cao in
Google Scholar
PubMed
Search for other papers by W Xiong in
Google Scholar
PubMed
Search for other papers by J Zhang in
Google Scholar
PubMed
Search for other papers by Q Zhou in
Google Scholar
PubMed
Search for other papers by H Wei in
Google Scholar
PubMed
Search for other papers by C Liang in
Google Scholar
PubMed
Search for other papers by J Deng in
Google Scholar
PubMed
Search for other papers by T Li in
Google Scholar
PubMed
Search for other papers by S Yang in
Google Scholar
PubMed
Search for other papers by L Xu in
Google Scholar
PubMed
It has been documented that stress or glucocorticoids have conflicting effects on memory under different conditions. However, it is not fully understood why stress can either impair or enhance memory. Here, we have examined the performance of six age groups of Wistar rats in a water maze spatial task to evaluate the effects of stress under different conditions. We found that the impairment or enhancement effect of an 'elevated platform' (EP) stress on memory was dependent on previous stress experience and on age. EP stress impaired memory retrieval in water maze naive animals, but enhanced rather than impaired memory retrieval in young water maze stress-experienced animals. Furthermore, exogenously applied corticosterone or foot shock stress before water maze training prevented the impairment of memory retrieval that should be induced by treatment with corticosterone or foot shock before the 'probe trial'. Again, memory retrieval was enhanced in young animals under these conditions, and this enhancement can be prevented by the glucocorticoid receptor antagonist RU 38486. Thus, glucocorticoid receptor activation not only induced impairment of memory but also increased the capacity of young animals to overcome a later stress. The present findings suggest that the effect of stress on memory can be switched from impairment to enhancement dependent on both stress experience and age.
Search for other papers by Shi-Yan Li in
Google Scholar
PubMed
Search for other papers by Cindy X Fang in
Google Scholar
PubMed
Search for other papers by Nicholas S Aberle II in
Google Scholar
PubMed
Search for other papers by Bonnie H Ren in
Google Scholar
PubMed
Search for other papers by Asli F Ceylan-Isik in
Google Scholar
PubMed
Search for other papers by Jun Ren in
Google Scholar
PubMed
Insulin-like growth factor-I (IGF-1) ameliorates cardiac dysfunction in diabetes although the mechanism of action remains poorly understood. This study examined the role of PI-3 kinase/Akt/mammalian target of rapamycin (mTOR) and calcineurin pathways in cardiac effects of IGF-1 against glucose toxicity. Adult rat ventricular myocytes were cultured for 8 h with either normal (NG, 5.5 mM) or high (HG, 25.5 mM) glucose, in the presence or absence of IGF-1 (10–500 nM), the PI-3 kinase/Akt inhibitor LY294002 (10 μM), the mTOR inhibitor rapamycin (20 μM) or the calcineurin inhibitors cyclosporin A (5 μM) or FK506 (10 mg/l). Mechanical properties were evaluated using an IonOptix MyoCam system. HG depressed peak shortening (PS), reduced maximal velocity of shortening/relengthening (± dl/dt) and prolongs time-to-90% relengthening (TR90), which were abolished by IGF-1 (100 and 500 nM). Interestingly, the IGF-1-elicited protective effect against HG was nullified by either LY294002 or rapamycin, but not by cyclosporine A or FK506. None of the inhibitors affected cell mechanics. Western blot analysis indicated that HG and IGF-1 stimulated phosphorylation of Akt and mTOR. HG also activated p70s6k and suppressed GSK-3β phosphorylation. However, the HG-induced alterations in phosphorylation of Akt, mTOR, p70s6k and GSK-3β were significantly reversed by IGF-1. Protein expression of Akt, mTOR, p70s6k, GSK-3β, SERCA2a and phospholamban was unaffected by HG, IGF-1 or rapamycin. Rapamycin significantly enhanced Akt phosphorylation whereas it inhibited mTOR phosphorylation. Collectively, our data suggest that IGF-1 may provide cardiac protection against glucose in part through a PI-3 kinase/Akt/mTOR/ p70s6k-dependent and calcineurin-independent pathway.
Adelaide Medical School, The University of Adelaide, Adelaide, Australia
Search for other papers by Harleen Kaur in
Google Scholar
PubMed
Nutrition and Health Program, Health and Biosecurity Business Unit, Commonwealth Scientific and Industrial Research Organisation, Adelaide, Australia
Search for other papers by Beverly S Muhlhausler in
Google Scholar
PubMed
Search for other papers by Pamela Su-Lin Sim in
Google Scholar
PubMed
Nutrition, Diabetes & Gut Health, Lifelong Health Theme, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, Australia
Search for other papers by Amanda J Page in
Google Scholar
PubMed
Nutrition, Diabetes & Gut Health, Lifelong Health Theme, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, Australia
Search for other papers by Hui Li in
Google Scholar
PubMed
Nutrition, Diabetes & Gut Health, Lifelong Health Theme, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, Australia
Search for other papers by Maria Nunez-Salces in
Google Scholar
PubMed
Adelaide Medical School, The University of Adelaide, Adelaide, Australia
Nutrition, Diabetes & Gut Health, Lifelong Health Theme, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, Australia
Search for other papers by Georgia S Clarke in
Google Scholar
PubMed
Search for other papers by Lili Huang in
Google Scholar
PubMed
Adelaide Medical School, The University of Adelaide, Adelaide, Australia
Search for other papers by Rebecca L Wilson in
Google Scholar
PubMed
Search for other papers by Johannes D Veldhuis in
Google Scholar
PubMed
Search for other papers by Chen Chen in
Google Scholar
PubMed
Adelaide Medical School, The University of Adelaide, Adelaide, Australia
Search for other papers by Claire T Roberts in
Google Scholar
PubMed
Adelaide Medical School, The University of Adelaide, Adelaide, Australia
Search for other papers by Kathryn L Gatford in
Google Scholar
PubMed
Circulating growth hormone (GH) concentrations increase during pregnancy in mice and remain pituitary-derived. Whether abundance or activation of the GH secretagogue ghrelin increase during pregnancy, or in response to dietary octanoic acid supplementation, is unclear. We therefore measured circulating GH profiles in late pregnant C57BL/6J mice and in aged-matched non-pregnant females fed with standard laboratory chow supplemented with 5% octanoic or palmitic (control) acid (n = 4–13/group). Serum total and acyl-ghrelin concentrations, stomach and placenta ghrelin mRNA and protein expression, Pcsk1 (encoding prohormone convertase 1/3) and Mboat4 (membrane bound O-acyl transferase 4) mRNA were determined at zeitgeber (ZT) 13 and ZT23. Total and basal GH secretion were higher in late pregnant than non-pregnant mice (P < 0.001), regardless of diet. At ZT13, serum concentrations of total ghrelin (P = 0.004), but not acyl-ghrelin, and the density of ghrelin-positive cells in the gastric antrum (P = 0.019) were higher, and gastric Mboat4 and Pcsk1 mRNA expression were lower in pregnant than non-pregnant mice at ZT23. In the placenta, ghrelin protein was localised mostly to labyrinthine trophoblast cells. Serum acyl-, but not total, ghrelin was lower at mid-pregnancy than in non-pregnant mice, but not different at early or late pregnancy. In conclusion, dietary supplementation with 5% octanoic acid did not increase activation of ghrelin in female mice. Our results further suggest that increases in maternal GH secretion throughout murine pregnancy are not due to circulating acyl-ghrelin acting at the pituitary. Nevertheless, time-dependent increased circulating total ghrelin could potentially increase ghrelin action in tissues that express the acylating enzyme and receptor.